BC Week In Review | Jan 12, 2015
Company News

Mylan sales and marketing update

Mylan launched a generic version of Orapred ODT prednisolone from Shionogi & Co. Ltd. (Tokyo:4507, Osaka, Japan) in the U.S. Mylan said its generic is the first generic version of Orapred ODT available in the...
BC Week In Review | Sep 15, 2014
Company News

Eisai, Concordia deal

Eisai will sell to Concordia U.S. and Puerto Rican commercialization rights to anticonvulsant Zonegran zonisamide. Eisai will receive $90 million in cash and the companies are expected to close a supply deal under which Eisai...
BC Week In Review | Jan 6, 2014
Clinical News

Ulesfia benzyl alcohol lotion regulatory update

On Dec. 30, 2013, Concordia said it submitted a regulatory application to Health Canada for Ulesfia benzyl alcohol lotion to treat head lice. Concordia said it will seek a commercialization partner in Canada for the...
BC Week In Review | May 13, 2013
Company News

Concordia, Shionogi sales and marketing update

Concordia acquired from Shionogi rights to ADHD drug Kapvay clonidine and oral disintegrating tablet and oral solution formulations of pulmonary and allergy drug Orapred prednisolone. Concordia also received exclusive rights to head lice drug Ulesfia...
BC Week In Review | Jan 16, 2012
Company News

Concordia, Kadmon deal

Kadmon acquired salirasib ( KD032 ) from Concordia. The Ras antagonist is in Phase II testing to treat solid tumors. MTS Health Partners advised Concordia. Financial terms were not disclosed. Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528, Osaka,...
BC Week In Review | Sep 6, 2010
Company News

Concordia, Ono Pharmaceutical deal

Concordia granted Ono exclusive rights to develop and commercialize salirasib in Japan. The Ras antagonist has completed a Phase IIa trial for non-small cell lung cancer (NSCLC) and a Phase I/II trial for pancreatic and...
BC Extra | Sep 2, 2010
Company News

Concordia, Ono in deal for salirasib

Concordia Pharmaceuticals Inc. (Fort Lauderdale, Fla.) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528) exclusive rights to develop and commercialize salirasib in Japan. The Ras antagonist has completed a Phase IIa trial in non-small cell lung...
BC Innovations | Jul 30, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer RAB11 family interacting protein 1 (RAB11FIP1; RCP) In vitro and mouse studies suggest that inhibiting RCP could help treat breast cancer. RCP is...
BC Week In Review | May 25, 2009
Clinical News

Salirasib: Phase II data

Data from 27 evaluable patients in an ongoing, open-label Phase II trial showed that 10 weeks of oral salirasib produced stable disease in 5 (26%) of 19 previously treated patients with K-Ras mutations and in...
BC Week In Review | May 25, 2009
Clinical News

Salirasib: Phase I/II data

Data from a Phase I/II trial in 13 previously untreated patients showed that twice-daily 400-800 mg salirasib plus gemcitabine led to progression-free survival of 4.7 months and a median survival of >10.8 months. The 1-year...
Items per page:
1 - 10 of 13
BC Week In Review | Jan 12, 2015
Company News

Mylan sales and marketing update

Mylan launched a generic version of Orapred ODT prednisolone from Shionogi & Co. Ltd. (Tokyo:4507, Osaka, Japan) in the U.S. Mylan said its generic is the first generic version of Orapred ODT available in the...
BC Week In Review | Sep 15, 2014
Company News

Eisai, Concordia deal

Eisai will sell to Concordia U.S. and Puerto Rican commercialization rights to anticonvulsant Zonegran zonisamide. Eisai will receive $90 million in cash and the companies are expected to close a supply deal under which Eisai...
BC Week In Review | Jan 6, 2014
Clinical News

Ulesfia benzyl alcohol lotion regulatory update

On Dec. 30, 2013, Concordia said it submitted a regulatory application to Health Canada for Ulesfia benzyl alcohol lotion to treat head lice. Concordia said it will seek a commercialization partner in Canada for the...
BC Week In Review | May 13, 2013
Company News

Concordia, Shionogi sales and marketing update

Concordia acquired from Shionogi rights to ADHD drug Kapvay clonidine and oral disintegrating tablet and oral solution formulations of pulmonary and allergy drug Orapred prednisolone. Concordia also received exclusive rights to head lice drug Ulesfia...
BC Week In Review | Jan 16, 2012
Company News

Concordia, Kadmon deal

Kadmon acquired salirasib ( KD032 ) from Concordia. The Ras antagonist is in Phase II testing to treat solid tumors. MTS Health Partners advised Concordia. Financial terms were not disclosed. Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528, Osaka,...
BC Week In Review | Sep 6, 2010
Company News

Concordia, Ono Pharmaceutical deal

Concordia granted Ono exclusive rights to develop and commercialize salirasib in Japan. The Ras antagonist has completed a Phase IIa trial for non-small cell lung cancer (NSCLC) and a Phase I/II trial for pancreatic and...
BC Extra | Sep 2, 2010
Company News

Concordia, Ono in deal for salirasib

Concordia Pharmaceuticals Inc. (Fort Lauderdale, Fla.) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528) exclusive rights to develop and commercialize salirasib in Japan. The Ras antagonist has completed a Phase IIa trial in non-small cell lung...
BC Innovations | Jul 30, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer RAB11 family interacting protein 1 (RAB11FIP1; RCP) In vitro and mouse studies suggest that inhibiting RCP could help treat breast cancer. RCP is...
BC Week In Review | May 25, 2009
Clinical News

Salirasib: Phase II data

Data from 27 evaluable patients in an ongoing, open-label Phase II trial showed that 10 weeks of oral salirasib produced stable disease in 5 (26%) of 19 previously treated patients with K-Ras mutations and in...
BC Week In Review | May 25, 2009
Clinical News

Salirasib: Phase I/II data

Data from a Phase I/II trial in 13 previously untreated patients showed that twice-daily 400-800 mg salirasib plus gemcitabine led to progression-free survival of 4.7 months and a median survival of >10.8 months. The 1-year...
Items per page:
1 - 10 of 13